UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39408 Lucid Group, Inc. (Exact name of registrant as specified in its charter) Delaware 85-0891392 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40406 ZIPRECRUITER, INC. (Exact name of registrant as specified in its charter) Delaware 27-2976158 (State or other jurisdiction of incorporation or organization) (I.R.S ...

Financial Performance - For the nine months ended September 30, 2025, the company reported net losses of $86.1 million, compared to $60.9 million for the same period in 2024, indicating a year-over-year increase of approximately 41% in losses[86]. - Net loss for the three months ended September 30, 2025, was $29.9 million, compared to a net loss of $24.0 million in 2024, representing an increase of $5.9 million[98]. - Total operating expenses for the nine months ended September 30, 2025, were $96.2 million, an increase of $21.8 million from $74.4 million in 2024[104]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $71.5 million, compared to $50.2 million in 2024, reflecting an increase of $21.3 million[112]. - Research and development expenses increased to $25.5 million for the three months ended September 30, 2025, compared to $22.7 million in 2024, reflecting a $2.8 million increase[99]. - Research and development expenses for the nine months ended September 30, 2025, totaled $74.7 million, an increase of $16.8 million from $57.9 million in 2024[105]. - General and administrative expenses rose to $7.5 million for the three months ended September 30, 2025, up from $5.9 million in 2024, primarily due to higher personnel costs[100]. - Other income decreased to $3.1 million for the three months ended September 30, 2025, down from $4.6 million in 2024, a decline of $1.5 million[101]. - The company reported a decrease in total other income for the nine months ended September 30, 2025, to $10.1 million from $13.5 million in 2024, a decline of $3.4 million[108]. Cash and Funding - As of September 30, 2025, the company had an accumulated deficit of $337.4 million and cash, cash equivalents, and marketable securities totaling $274.9 million[86]. - The company expects to continue incurring significant operating losses, particularly as it conducts preclinical studies and clinical trials, and anticipates that its cash reserves will be sufficient to fund operations through at least 2027[88]. - The company plans to finance its operations through equity offerings and other capital sources until it can generate significant revenue from product sales[88]. - The company believes that existing cash, cash equivalents, and marketable securities will be sufficient to meet anticipated operating expenses and capital expenditures through at least 2027[119]. - Future capital requirements will depend on various factors, including the ability to generate substantial product revenues to support the cost structure[120]. - The company may finance cash needs through equity offerings, debt financings, or other capital sources, but may be unable to raise additional funds on favorable terms[120]. - The company has material cash requirements for expected operating expenses related to clinical trials and research and development activities[117]. Clinical Development - The lead program, dabogratinib, is currently in multiple Phase 2 clinical studies targeting pediatric achondroplasia and low-grade bladder cancer, with initial results expected in the second half of 2026[78][79]. - In the SURF301 study, 54.5% of patients with FGFR3+ metastatic urothelial carcinoma achieved a confirmed partial response when receiving doses of dabogratinib ≥ 90 mg once daily[81]. - TYRA-430 is currently being evaluated in a global Phase 1 study for advanced hepatocellular carcinoma, with patient dosing commenced in April 2025[83]. - The research and development expenses are expected to increase substantially as the company advances its product candidates through clinical trials and expands its pipeline[90]. - The process of conducting preclinical studies and clinical trials is costly, and the timing of progress and expenses is uncertain[119]. Risks and Uncertainties - The costs and timing of manufacturing for current or future product candidates, including commercial scale manufacturing, are uncertain[121]. - The company faces risks related to the costs and timing of regulatory review of current or future product candidates[121]. - The company may need to relinquish valuable rights to technologies or future revenue streams if additional funds are raised through collaborations[122]. - As of September 30, 2025, there have been no material changes to critical accounting policies and estimates compared to the previous annual report[125]. - There have been no material changes surrounding market risk, including interest rate risk and inflation risk, from the previous annual report[127]. Other Information - The company completed a private placement on February 6, 2024, raising approximately $199.6 million in net proceeds[109]. - As of September 30, 2025, the total future aggregate operating lease commitments were $8.0 million, with approximately $0.2 million due during 2025, and the remaining due from 2026 through 2033[124].

Financial Performance - Total revenues for Q3 2025 increased by 5% to $11.1 billion compared to Q3 2024, driven by positive demand and contributions from acquisitions[115] - Net income for Q3 2025 rose by $130 million to $1.5 billion, with an adjusted EBITDA of $2.7 billion, reflecting a 10% increase[115] - For the nine months ended September 30, 2025, total revenues reached $28.0 billion, also a 5% increase from the same period in 2024[127] - Gross profit for Q3 2025 was $4.3 billion, a 6% increase from Q3 2024, with a gross profit margin of 38.9%[128] - The net income margin for Q3 2025 was 13.7%, an increase of 50 basis points from the previous year[115] - Net income for the three months ended September 30, 2025, was $1.5 billion, an increase of $130 million from the comparable period in 2024[142] - Net income for the nine months ended September 30, 2025, was $3.607 billion, compared to $1.050 billion for the year ended December 31, 2024[207] Acquisitions and Investments - CRH completed nine acquisitions in Q3 2025 for a total consideration of $2.5 billion, compared to $1.4 billion in Q3 2024[117] - Net cash used in investing activities was $4.705 billion for the nine months ended September 30, 2025, with $3.1 billion spent on acquisitions, down from $3.9 billion in 2024[189] Shareholder Returns - Cash returned to shareholders through share buybacks was $0.9 billion, a decrease of $0.1 billion compared to the first nine months of the prior year[121] - The company repurchased approximately 9.6 million Ordinary Shares for a total consideration of $0.9 billion in the first nine months of 2025[183] Revenue Breakdown - Total revenues for Americas Materials Solutions for the three months ended September 30, 2025, were $5.637 billion, a 6% increase compared to the same period in 2024[148] - Total revenues for International Solutions for the nine months ended September 30, 2025, were $10.004 billion, an 8% increase compared to the same period in 2024[166] - Total revenues in Essential Materials for the nine months ended September 30, 2025, increased by 9% compared to the prior year, driven by favorable pricing and acquisitions[167] EBITDA and Margins - Adjusted EBITDA for Americas Building Solutions for the three months ended September 30, 2025, was $432 million, a 22% increase from the comparable period in 2024[156] - Adjusted EBITDA for International Solutions increased by 19% to $1.578 billion for the nine months ended September 30, 2025[166] - Adjusted EBITDA margin for Americas Materials Solutions was 27.6% for the three months ended September 30, 2025, down from 28.0% in the prior year[148] - Adjusted EBITDA in International Solutions increased by 19% compared to the same period in 2024, with a 150bps rise in adjusted EBITDA margin[169] Expenses and Costs - Selling, general and administrative expenses for Q3 2025 were $2.3 billion, up 7% from the same period in 2024, primarily due to increased labor costs[132] - Interest expense for Q3 2025 was $209 million, an increase of $45 million from Q3 2024, attributed to higher gross debt balances[136] Cash Flow and Debt - Net cash provided by operating activities was $2.710 billion for the nine months ended September 30, 2025, an increase of $0.451 billion from $2.259 billion in 2024[187] - Net Debt at September 30, 2025, was $15.006 billion, an increase from $10.532 billion at December 31, 2024[176] - As of September 30, 2025, the Company had a total debt of $18.8 billion, with $3.982 billion due within one year and $6.075 billion due in more than five years[198] Tax and Rates - Effective tax rate for the three months ended September 30, 2025, was 22%, down from 28% in the comparable period in 2024[139] Currency and Commodity Risks - A 10% weakening in foreign currency exchange rates versus the U.S. Dollar would increase the fair market value of foreign currency contracts by approximately $20 million as of September 30, 2025[222] - The Company manages commodity price risks through negotiated supply contracts and forward contracts, focusing on materials like oil, electricity, coal, and carbon credits[223] - Derivative hedging programs are in place to neutralize variability from changes in commodity indices, with a timeframe of up to four years[224]

Revenue Performance - Revenue for Q3 2025 was $115.6 million, representing a 13% increase compared to Q3 2024[5] - Total revenue for Q3 2025 was $115.593 million, up from $102.638 million in Q3 2024, representing a growth of 12.5%[33] - Subscription revenue increased to $114.720 million in Q3 2025 from $101.813 million in Q3 2024, a rise of 12.6%[33] - For Q4 2025, the company expects total revenue between $118.2 million and $119.0 million[13] - For the full year 2025, total revenue is projected to be between $454.9 million and $455.7 million[13] Customer Metrics - The number of customers contributing over $10,000 in ARR grew to 9,756, a 7% increase year-over-year[12] - The number of customers contributing over $50,000 in ARR increased to 1,947, up 21% compared to the previous year[12] - The number of customers contributing more than $10,000 in ARR is a key metric indicating potential for future growth, although specific numbers were not disclosed[27] Profitability and Income - Non-GAAP operating income was $13.7 million, compared to $7.5 million in Q3 2024[5] - The net loss for Q3 2025 was $9.381 million, an improvement compared to a net loss of $17.087 million in Q3 2024, reflecting a reduction of 45.5%[33] - Non-GAAP net income for Q3 2025 was $13,464,000, compared to $7,312,000 in Q3 2024, reflecting an 84.5% increase[49] - Non-GAAP net income per share is expected to be between $0.15 and $0.17 based on approximately 59.3 million weighted-average shares[13] Cash and Cash Equivalents - Cash and cash equivalents totaled $90.6 million as of September 30, 2025, down from $101.5 million as of June 30, 2025[5] - The company ended the period with cash, cash equivalents, and restricted cash totaling $92,572,000, up from $86,855,000 at the end of Q3 2024[47] Operating Expenses and Compensation - Operating expenses for Q3 2025 totaled $98.920 million, slightly up from $96.285 million in Q3 2024, an increase of 2.7%[33] - The total stock-based compensation expense for Q3 2025 was $19.029 million, down from $23.186 million in Q3 2024, a decrease of 18%[34] - Stock-based compensation expense for Q3 2025 was $19,029,000, down from $23,186,000 in Q3 2024[49] Assets and Obligations - Current remaining performance obligations (cRPO) reached $258.5 million, up 17% year-over-year[5] - Total assets increased to $481.396 million as of September 30, 2025, compared to $428.341 million at the end of 2024, marking a growth of 12.4%[40] - Current remaining performance obligations (cRPO) indicate contracted revenue expected to be recognized in the next 12 months, although specific figures were not provided[26] Cash Flow - Net cash provided by operating activities for the nine months ended September 30, 2025, was $32,492,000, compared to $22,179,000 for the same period in 2024, representing a 46.5% increase[49] - Non-GAAP free cash flow for Q3 2025 was $10,339,000, an increase of 10.9% from $9,311,000 in Q3 2024[49] - Cash flows from investing activities resulted in a net cash outflow of $49,635,000 in Q3 2025, compared to a net inflow of $36,714,000 in Q3 2024[47] Strategic Initiatives - The company launched a new Canva integration and expanded its collaboration with Salesforce to enhance social customer care[13] - The company made payments for business acquisitions totaling $50,333,000 in Q3 2025, significantly higher than $1,409,000 in Q3 2024[47]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 10-Q (Mark One) Commission File Number 001-32924 GREEN PLAINS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1811 Aksarben Drive, Omaha, NE 68106 (402) 884-8700 ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ende ...

Financial Performance - Net sales for the three months ended September 30, 2025, were $363.9 million, a 40% increase from $260.4 million in the same period of 2024[118] - Gross profit increased to $119.8 million, representing a 43% increase from $83.5 million year-over-year[118] - Operating income rose significantly to $51.3 million, compared to $17.7 million in the prior year[118] - Adjusted EBITDA for the three months ended September 30, 2025, was $61.9 million, an increase of $31.2 million compared to $30.7 million in 2024[139] - Net income for the three months ended September 30, 2025, was $26.5 million, an increase of $19.6 million compared to $7.0 million in 2024[139] - Adjusted net income for the three months ended September 30, 2025, was $29.8 million, an increase of $15.8 million compared to $14.1 million in 2024[141] Sales and Revenue Contributions - The acquisition of Zoetis's medicated feed additive portfolio contributed $288.7 million to overall net sales, with $80.5 million recorded in the three months ended September 30, 2025[104] - Animal Health segment net sales increased by $100.9 million or 55%, driven by an $87.4 million increase in MFAs and other products due to the acquisition and higher demand in North and South America[125] - Sales of Mecadox (carbadox) for the twelve months ended September 30, 2025, were approximately $22 million[116] - Performance Products segment net sales decreased by $1.4 million or 7% due to lower demand for ingredients used in personal care products[128] Expenses and Financial Obligations - Interest expense increased by 58% to $12.1 million from $7.6 million in the previous year[118] - Selling, general and administrative expenses increased by 4% to $68.5 million from $65.8 million year-over-year[118] - Selling, general and administrative expenses (SG&A) increased by $2.7 million or 4% to $68.5 million, with a significant portion attributed to employee-related costs[131] - Interest expense for the three months ended September 30, 2025, was $12.1 million, an increase of $4.4 million due to higher debt levels from the acquisition financing[133] Taxation - The effective tax rate for the three months ended September 30, 2025, was 26.9%, slightly lower than 27.5% in the prior year[118] - The effective income tax rate for the three months ended September 30, 2025, was 26.9%, slightly lower than 27.5% in 2024[135] Cash Flow and Liquidity - For the three months ended September 30, 2025, the company reported a net cash provided by operating activities of $9.3 million, a decrease of $3.3 million compared to $12.6 million in the same period of 2024[144] - Total cash used in investing activities was $21.0 million, which included capital expenditures of $13.8 million aimed at expanding production capacity[146] - Financing activities generated $16.3 million in net cash, primarily from net revolver borrowings of $28.0 million[147] - As of September 30, 2025, the company had cash and cash equivalents and short-term investments totaling $85.3 million, an increase from $77.0 million as of June 30, 2025[149] - The company's working capital increased to $498.8 million, up from $456.3 million as of June 30, 2025, with a current assets to current liabilities ratio of 2.98:1[149] - The company expects adequate liquidity for at least the next twelve months, despite potential risks from macroeconomic conditions[148] Regulatory and Market Risks - The company has requested a full evidentiary hearing regarding the regulatory status of carbadox, which could impact future sales[116] - A material portion of the company's sales and gross profits are generated by antibacterials and related products, which are subject to regulatory scrutiny[167] - The company faces risks from outbreaks of animal diseases that could significantly reduce demand for its products or availability of raw materials[167] - The company is exposed to market risks from adverse changes in interest rates, foreign currency exchange rates, and commodity prices[171] - The company has substantial levels of indebtedness and related debt-service obligations, which may impact financial stability[170] - The company is dependent on suppliers having current regulatory approvals, which can impact raw material availability[170] - The company is subject to risks related to changes in tax rates and exposure, which could affect profitability[170] Strategic Initiatives - The company has acquired a medicated feed additive product portfolio from Zoetis Inc., which it aims to successfully integrate[170] - The company utilizes foreign currency contracts and interest rate swaps to hedge exposure to market risks, but does not eliminate the effects of changing market conditions[171] - The company relies on the continued operation of its manufacturing facilities and the application of its intellectual property for business continuity[170] - The company is affected by competition from both large and small companies, some of which have greater resources[167] Dividends - The company declared a cash dividend of $0.12 per share on Class A and Class B common stock, payable on December 17, 2025[151]

Financial Performance - Total revenues for the three months ended September 30, 2025, were $1,239.7 million, an increase from $1,178.9 million for the same period in 2024, representing a growth of 5.2%[23] - Earned premiums for the nine months ended September 30, 2025, reached $3,352.0 million, compared to $3,134.1 million for the same period in 2024, reflecting a year-over-year increase of 7.0%[23] - Net (loss) income attributable to Kemper Corporation for the three months ended September 30, 2025, was $(21.0) million, a decrease from $73.7 million in the same period of 2024[23] - For the three months ended September 30, 2025, Kemper Corporation reported a net loss of $24.2 million, compared to a net income of $72.2 million for the same period in 2024[24] - Total comprehensive income for the nine months ended September 30, 2025, was $220.3 million, down from $325.1 million in the same period of 2024[24] - For the nine months ended September 30, 2025, the net income was $142.6 million, a decrease from $216.8 million for the same period in 2024, reflecting a decline of approximately 34.2%[39] Expenses and Losses - Total expenses for the three months ended September 30, 2025, were $1,272.8 million, compared to $1,088.2 million for the same period in 2024, marking an increase of 16.9%[23] - Policyholders' benefits and incurred losses and loss adjustment expenses for the three months ended September 30, 2025, were $924.6 million, up from $769.3 million in the same period of 2024, indicating a rise of 20.2%[23] - The company reported a net investment income of $104.8 million for the three months ended September 30, 2025, down from $111.1 million in the same period of 2024, a decline of 5.0%[23] - The company experienced a remeasurement loss related to the deferred profit liability within the Life insurance business of $0.9 million for the three months ended September 30, 2025[23] Assets and Liabilities - The company's total assets decreased to $12,443.4 million as of September 30, 2025, from $12,630.4 million at the end of 2024[27] - Insurance reserves increased to $6,123.6 million as of September 30, 2025, compared to $5,811.6 million at December 31, 2024, reflecting a growth of 5.3%[30] - Kemper's total investments decreased to $8,602.6 million as of September 30, 2025, from $8,888.5 million at December 31, 2024[27] - The company's long-term debt remained stable at approximately $943.1 million as of September 30, 2025, compared to $941.7 million at December 31, 2024[30] - Kemper Corporation's shareholders' equity decreased to $2,721.6 million as of September 30, 2025, from $2,784.3 million at the end of 2024[30] Shareholder Actions - Cash dividends paid to shareholders for the three months ended September 30, 2025, amounted to $19.7 million, with a dividend of $0.32 per share, compared to $20.3 million and $0.31 per share in the same period of 2024[38] - The number of common shares outstanding decreased from 64.4 million as of June 30, 2024, to 60.2 million as of September 30, 2025, representing a reduction of approximately 6.5%[39] - The company repurchased common stock totaling $218.8 million during the three months ended September 30, 2025, compared to $25.0 million in the same period of 2024[38] Regulatory and Competitive Environment - The company anticipates continued challenges in the regulatory environment and increased competition affecting future performance[12] - Kemper is focused on integrating acquired businesses and implementing significant operational changes to enhance efficiency and competitiveness[19] Investment Performance - The allowance for credit losses on fixed maturities increased to $15.7 million in 2025 from $10.7 million in 2024[27] - The company reported a comprehensive loss of $227.1 million as of September 30, 2025, compared to a comprehensive loss of $252.5 million as of September 30, 2024, indicating an improvement in overall financial health[39] - The total fixed maturities investments amounted to $4,939.1 million, with unrealized losses of $728.0 million, including $793.8 million in fair value for less than 12 months and $4,145.3 million for 12 months or longer[75] Taxation - For the three months ended September 30, 2025, the income tax benefit was $7.9 million, or 27.3% of income before income taxes, compared to an expense of $18.9 million, or 20.4% for the same period in 2024[186] - The company has no unrecognized tax benefits as of September 30, 2025, and no liabilities for accrued interest and penalties for the nine months ended September 30, 2025[187] Legal and Compliance - The company is involved in legal proceedings but does not believe any pending legal matters will materially affect its financial statements[189] - There have been no material changes to the company's disclosures about market risk since the 2024 Annual Report[316]

Revenue Performance - Total revenue decreased by $1.3 million, or 1.6%, to $82.3 million compared to $83.7 million in the same period of 2024[6]. - Company-owned restaurant sales for the thirteen weeks ended September 28, 2025, were $74,358,000, a decrease from $75,599,000 in the same period of 2024[27]. Profitability and Loss - Net loss increased to $24.5 million compared to $16.2 million in the same period of the prior year[10]. - The income from operations for the thirteen weeks ended September 28, 2025, was a loss of $13,365,000, compared to a loss of $3,590,000 in the same period of 2024[27]. - Adjusted EBITDA increased to $3.0 million compared to $2.3 million in the prior year[10]. - Adjusted EBITDA for the thirty-nine weeks ended September 28, 2025, was $13,206,000, down from $16,560,000 in the prior year[26]. Cost Management - General and administrative expenses rose by $12.3 million, or 172.1%, to $19.5 million, primarily due to store closure costs and non-cash impairments[9]. - General and administrative expenses increased to $46,033,000 for the thirty-nine weeks ended September 28, 2025, from $21,160,000 in the prior year[27]. - Labor and benefits costs decreased by $0.9 million, or 3.5%, to $23.9 million, as a percentage of restaurant sales, it was 32.1% in 2025 compared to 32.8% in 2024[8]. - Food and beverage costs decreased by $0.5 million, or 2.3%, to $20.3 million, representing 27.4% of restaurant sales in 2025[7]. Restaurant Performance - Restaurant contribution margin improved to 9.6%, with Twin Peaks at 17.0% and Smokey Bones at (0.3%) compared to 8.7% in the prior year[10]. - The restaurant-level contribution margin for the thirty-nine weeks ended September 28, 2025, was 10.8%, compared to 11.8% for the same period in 2024[27]. - The restaurant-level contribution for the thirty-nine weeks ended September 28, 2025, was $25,071,000, compared to $28,684,000 in the same period of 2024[27]. - Twin Peaks same-store sales declined by 4.1%[10]. Strategic Initiatives - The company closed 11 underperforming Smokey Bones locations and is targeting improved profitability for the brand starting early 2026[4]. - The company plans to expand its pipeline for 2026 with both franchised and company-owned opportunities[4]. Other Expenses - The company incurred store closure expenses of $8,285,000 for the thirty-nine weeks ended September 28, 2025[26]. - The company reported a depreciation and amortization expense of $13,758,000 for the thirty-nine weeks ended September 28, 2025, down from $17,500,000 in the previous year[26]. - The litigation cost for the thirteen weeks ended September 28, 2025, was $850,000, consistent with the prior year[26].

Financial Performance - Rental income for the three months ended September 30, 2025, was $25,800 thousand, down from $26,731 thousand in the same period of 2024, a decrease of about 3.5%[19] - The net loss attributable to common shareholders for the three months ended September 30, 2025, was $3,499 thousand, compared to a loss of $24,395 thousand in the same period of 2024, showing an improvement of about 86%[19] - The company reported a net income of $3,780 thousand for the three months ended September 30, 2025, contrasting with a net loss of $26,549 thousand in the same period of 2024[21] - For the nine months ended September 30, 2025, the net loss was $336.381 million, compared to a net loss of $25.180 million for the same period in 2024[28] - The company reported a significant net loss of $265,300,000 for the quarter ending June 30, 2025[25] - Total comprehensive loss for the quarter ending June 30, 2024, was $19,195,000[23] Assets and Liabilities - Total assets decreased from $2,676,232 thousand as of December 31, 2024, to $1,986,374 thousand as of September 30, 2025, representing a decline of approximately 26%[16] - The total liabilities decreased from $1,524,210 thousand as of December 31, 2024, to $1,209,518 thousand as of September 30, 2025, a reduction of approximately 21%[16] - As of September 30, 2025, the company's total gross investment in real estate (excluding discontinued operations) was $1,263,937,000, down from $1,493,143,000 as of December 31, 2024[62] - The total real estate related to discontinued operations was $403,539,000 as of September 30, 2025, down from $995,152,000 as of December 31, 2024, indicating a reduction of about 59%[154] - The total real estate assets for industrial real estate net was $1,066,052,000 as of September 30, 2025, down from $1,100,936,000 as of December 31, 2024, a decrease of about 3%[154] Cash Flow and Investments - Cash and cash equivalents increased from $146,514 thousand as of December 31, 2024, to $326,085 thousand as of September 30, 2025, reflecting a growth of approximately 122%[16] - The net cash provided by operating activities for continuing operations was $2.715 million, an improvement from a net cash used of $1.608 million in 2024[28] - The company reported a net cash provided by investing activities of $450.282 million, significantly higher than $102.929 million in 2024[30] - The principal pay down of indebtedness for the credit facility was $200 million, compared to $10 million in the previous year[30] Real Estate Operations - The company is executing a strategic transition to an industrial-only real estate investment trust (REIT), focusing on growth in the industrial outdoor storage (IOS) sector[32] - The company completed the sale of 11 Office Discontinued Operations Properties during the nine months ended September 30, 2025[47] - The company acquired three industrial outdoor storage properties for a total purchase price of $57,106,000 during the three months ended September 30, 2025[65] - The company disposed of nine properties for a total gross sales price of $233,415,000 during the nine months ended September 30, 2025, resulting in a gain of $6,407,000[67] Shareholder Information - As of September 30, 2024, Peakstone Realty Trust reported total shareholders' equity of $1,132,171,000, with common shares totaling 36,377,254[23] - The company declared dividends to common shareholders amounting to $8,284,000 during the quarter ending June 30, 2024[23] - The company declared a cash dividend of $0.10 per common share for the quarter ended September 30, 2025, payable on or about October 17, 2025[155] - The Company had 36,790,867 common shares outstanding as of September 30, 2025, following its listing on the New York Stock Exchange on April 13, 2023[107][108] Debt and Interest Rates - The total consolidated debt as of September 30, 2025, was $1,050.8 million, down from $1,360.3 million as of December 31, 2024, reflecting a reduction of 22.7%[85] - The weighted average effective interest rate for the company's total debt was 5.46% as of September 30, 2025[85] - The Company has interest rate swaps with a notional amount of $550 million, effective from July 1, 2025, to July 1, 2029, converting SOFR to a weighted average fixed rate of 3.58%[96] - An increase of 100 basis points in interest rates would decrease future earnings and cash flows by approximately $1.9 million annually, considering the effect of interest rate swaps[272] Impairments and Expenses - The company experienced a significant real estate impairment provision of $18,195 thousand for the nine months ended September 30, 2025, compared to $50,774 thousand in the same period of 2024[19] - Total expenses for the nine months ended September 30, 2025, were $390,788,000, significantly higher than $50,493,000 in 2024, primarily due to a real estate impairment provision of $345,492,000[50] - The company recorded real estate impairments of $25.6 million related to eight Office Discontinued Operations Properties during the three months ended September 30, 2025, due to shortened anticipated hold periods and estimated selling prices[76] Other Financial Metrics - The accumulated deficit as of September 30, 2024, was $850,992,000, reflecting an increase from $826,597,000 as of June 30, 2024[23] - The fair value of total secured debt as of September 30, 2025, was $242,675, down from $250,766 as of December 31, 2024[106] - The Company recognized $70.6 million in lease income related to operating lease payments for the nine months ended September 30, 2025, compared to $74.1 million for the same period in 2024, indicating a decrease of 6.5%[133]